Navigation Links
Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis

EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company specialized in ophthalmology, announces today positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC). In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability to Vekacia(R) was excellent.

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In March 2006, Novagali received European Medicines Agency (EMEA) orphan drug designation for Vekacia(R) in the treatment of VKC.

The study was conducted by key experts and opinion leaders in the field of ocular allergy throughout Europe and Mediterranean area and lead by Pr David Ben Ezra, Hadassah Hebrew University Hospital, Jerusalem, who first reported on the use and potential efficacy of Cyclosporine A for the treatment of VKC.

Vekacia(R) is a topical Cyclosporine A cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy. This proprietary ophthalmic emulsion of Cyclosporine A will be the first therapeutic product dedicated to treatment of such a severe ocular condition.

"We achieved a major corporate milestone completing our first phase III clinical trial" declares Jerome Martinez, President & CEO of Novagali, "I am very enthusiastic about the confirmation of the high potential of Novasorb(R) cationic emulsion technology through the development of Vekacia(R) and its successful use in VKC. It is very encouraging for the other ongoing projects".

"It is a great satisfaction to b
'"/>




Page: 1 2

Related medicine technology :

1. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/25/2008)...AN MATEO, Calif., Aug. 25 /- Anthera ...utical company developing,anti-inflammatory drugs,...wer Recurrent Acute coronary events with Near-term... trial designed to examine the impact of,varesplad...f an Acute,Coronary Syndrome (ACS) event., The FR...
(Date:8/22/2008)...,395 Women Enrolled in Trial Sponsored by Medical ...wswire-FirstCall/ -- Indevus,Pharmaceuticals, Inc....f,enrollment in Protocol MDP 301, a Phase III clin...ginal microbicide for the prevention of HIV and ot...sponsored by the United,Kingdom,s Medical Research...
(Date:8/22/2008)...OCKVILLE, Md., Aug. 22 /- H...announced that it has completed the,enrollment and...2 trial of,HGS-ETR1 (mapatumumab) in combination w...atin as first-line therapy in advanced non-small c...com.com/cgi-bin/prnh/20080416/HGSLOGO ), "There ...
(Date:8/21/2008)...ANHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ --... E. coli O157:H7 expert T.G. Nagaraja has,been tap... both the,connection between feeding distillers, g...rategies to reduce the presence of the naturally o...received a $939,220 National Research Initiative i...
Breaking Medicine Technology:Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 2Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 4Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 5K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 1Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 4Investigational New Drug Application for Fat Melting Injections Cleared by the FDA 519 1Investigational New Drug Application for Fat Melting Injections Cleared by the FDA 519 2Probiotic good bugs may control gut infections 360 1Probiotic good bugs may control gut infections 360 2Two nanostructures are better than one 358 1Two nanostructures are better than one 358 2Two nanostructures are better than one 358 3Two nanostructures are better than one 358 4
...tinal Adenomas Suggesting,Possible Beneficial Medi...ORADO HILLS, Calif., March 07, 2007 /PRNewswire/ -...on the effect of rice bran,on the number of intest...January 9, 2007 online edition of the prestigious ...ent of Cancer Studies and,Molecular Medicine, at t...
...es to Further Reduce Antibodies,to Double-Stranded...all/ -- La Jolla,Pharmaceutical Company today anno...ngoing double-blind, placebo-controlled,randomized...s drug,candidate for systemic lupus erythematosus ...ata indicate that patients treated,with 900 mg or ...
Other Medicine Technology:British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 7
(Date:8/28/2008)...., Aug. 28 /PRNewswire/ -- The 2008 European,Hemod...ented to Redsense,Medical in recognition of its pi... device. "Redsense detects the loss of blood durin...ents"., The device consists of an alarm and a sen...ing fibre optic technology that sends signals,aler...
(Date:8/28/2008)...based in the Northeast region with more hires,plan...RRISBURG, Pa., Aug. 28 /PRNewswire-USNewswire/ -- ...d a Patient Safety Liaison for the,Northeast regio...,Pennsylvania Patient Safety Reporting System (PA-...zens., "Last year in focus groups with Pennsylvan...
(Date:8/28/2008)...st eating raw Mexican jalapeno and serrano peppers... -- U.S. health officials declared Thursday that t...at the consumer advisory against eating raw jalape...fted. , "Based on the available information an... Dr. Robert Tauxe, deputy director of the U.S. Cen...
(Date:8/28/2008).... 28 /PRNewswire/ -- Guava Technologies, Inc.,anno... Control Group to,provide drug discovery researche...s. This non-exclusive agreement is a key component...ogies. The initiative is a direct,response to a vo...gy to,support higher throughput research in a comp...
Breaking Medicine News(10 mins):Health News:Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award 2Health News:Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award 3Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Salmonella Outbreak Over, U.S. Says 2Health News:Salmonella Outbreak Over, U.S. Says 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3
...rchers from Queen's University in Kingston, Ontari...rward eye movement tests in the diagnosis of fetal...his condition called FASD affects children when mo...gnancy. To understand how eye movements, or oculom...
...roved meat and milk from cloned animals while it c.../ said Thursday that its customers and consumers d...n company owns Land O'Lakes and Horizon Organic, a...us surveys have shown that Americans are not inter...
...e providers from a variety of backgrounds and loca...Cancer// Society Lane Adams Quality of Life Award,...he Lane Adams Quality of Life Award recognizes ind...ation, leadership, and consistent excellence in pr...
...e groups are calling on the Federal Government to ...en// from stomach bugs. Rotavirus puts 10,000 Aus...more turning up at hospital emergency wards and at...mptoms of acute diarrhoea and vomiting. The rotav...
Other Medicine News:Health News:Milk from Cloned Cows is Not Welcome at the Nation's Biggest Milk Company 2Health News:American Cancer Society Honors Exemplary Cancer Caregivers 2Health News:Call for Rotavirus Vaccine Funding 2
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: